Trading Update

MedPal AI (AIM: MPAL), a UK-based digital health and artificial intelligence ("AI") company focused on health and wellness management, is pleased to provide a trading update on its pharmacy operations for December 2025 and that Novo Nordisk's Wegovy pill has now been approved by the FDA.

Trading Update - Pharmacy Operations

During December 2025, MedPal Limited processed 33,433 prescription orders through its automated pharmacy operations, generating turnover of approximately £325,000 at an average item value of £9.72. This represents month-on-month growth of approximately 16% compared with November 2025's 28,789 prescriptions, a particularly strong performance given the shortened trading month due to the Christmas period.

The continued scaling of prescription volumes reflects both the successful integration of the NHS Distance Selling Pharmacy ("DSP") contract and growing uptake of the Company's private weight loss service launched via MedPal.clinic.

FDA Approves First Oral GLP-1 for Weight Loss

On 22 December 2025, the US Food and Drug Administration ("FDA") approved Novo Nordisk's Wegovy pill (oral semaglutide 25mg), making it the first oral GLP-1 medication approved for weight management. This landmark approval represents a paradigm shift in obesity treatment, offering patients a once-daily pill alternative to weekly injections.

Clinical trials demonstrated that the oral formulation achieved weight loss of up to 16.6% in adherent patients over 64 weeks, a result that is comparable to the injectable form. The Directors believe this development will significantly expand the addressable market for GLP-1 therapies, as many patients who are reluctant to use injectable medications may now consider treatment. The oral format removes barriers such as needle aversion and refrigeration requirements, potentially bringing millions of new patients into the weight management market.

MedPal.clinic, powered by Google's Vertex AI platform, is well positioned to capitalise on this expanded market opportunity through its established AI-powered triage and prescription fulfilment capabilities.

Jason Drummond, CEO of MedPal AI, said:

"We are delighted with MedPal Limited's continued strong performance, achieving 16% month-on-month growth despite the Christmas period shortening our effective trading days. Processing approximately 33,000 prescriptions in December demonstrates the scalability and resilience of our automated dispensing infrastructure.

" We were also pleased to hear of the FDA's approval of the first oral GLP-1 for weight loss, which we expect to be transformative for the industry. By removing the barrier of injectable administration, we anticipate significant expansion of the patient population seeking treatment. MedPal.clinic's AI-first approach positions us to efficiently serve this growing market whilst maintaining the highest standards of clinical safety and patient care."

The Directors of the Company are responsible for the contents of this announcement.